The Lynx Group

ESMO 2013 Conference

Amsterdam, The Netherlands—The novel ALK/EGFR inhibitor known as AP26113 achieved good responses in reducing brain metastases in patients with crizotinib (Xalkori)-resistant and crizotinib-nave non–small-cell lung cancer (NSCLC), as well as radiographic regression of central nervous system (CNS) metastases.
Read Article

Amsterdam, The Netherlands—The antibody-conjugate ado-trastuzumab emtansine (Kadcyla), also known as T-DM1, prolonged progression-free survival (PFS) in advanced HER2-positive breast cancer in a heavily pretreated population, according to the final results of the phase 3 clinical trial TH3RESA.
Read Article

Amsterdam, The Netherlands—Although much progress has been made in cancer care over the past couple of decades, a report presented at the 2013 European Cancer Congress emphasizes that on a global scale, the impact is far from equitable.
Read Article

Amsterdam, The Netherlands—For the first time, a therapy for non–small-cell lung cancer (NSCLC) has achieved responses in smokers better than in nonsmokers. The antibody MPDL3280A also achieved good responses in squamous and adenoma histologic types of NSCLC.
Read Article

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to receive the free VBCC print publication or weekly e‑Newsletter.

I'd like to receive: